12 Gill Street
About ReForm Biologics
ReForm Biologics is a formulation innovator for protein therapeutics.
Our proprietary technology provides patented, FDA-friendly excipients for a wide range of therapeutic biologics. Using our platforms, drug companies can make life-saving medicines easier to administer, less immunogenic, more stable, and more efficient to produce. Click here to learn more about these breakthrough technologies.
By enhancing therapeutic protein formulations, ReForm’s technology helps to turn biologic molecules into biobetters in order to improve the patient experience. In addition, our formulation advancements offer an opportunity for extending a product’s lifecycle.
CEO: John M. Sorvillo Ph.D.
Co-Founder & CTO: David Soane, Ph.D.
CFO: Martha Groves
Please click here for ReForm Biologics' technology.
Please click here for ReForm Biologics' job opportunities.
17 articles with ReForm Biologics
3/19/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Brings 25 years of preclinical and clinical drug development experience to ReForm
ReForm Biologics , a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, announced the expansion of its patent portfolio with issuance of its first patent in China, Patent No. CN ZL20158003.
2/26/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
ReForm Biologics today announced it will expand its focus to develop a new generation of bio-innovative biologic medicines in-house to improve patient access, safety and convenience. As well, James (Jim) Sherblom has joined the board of directors of ReForm as chairman to lead the shift in strategy.
ReForm Biologics Announces the Issuance of U.S. and Japanese Patents for Therapeutic Protein Formulations
ReForm Biologics , a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, expanded its patent portfolio with the issuance of U.S. Patent No. 10,610,600 and its first patent in Japan, Japanese Patent No. 6674910. The U.S. patent, entitled “Stabilizing Excipients for Therapeutic Protein Formulations,” provides ReForm exclusive rights to therapeutic pr
ReForm Biologics and MilliporeSigma Announce a Licensing Agreement for Excipient Development and Commercialization
Feb. 10, 2020 12:30 UTC WOBURN, Mass.--( BUSINESS WIRE )-- ReForm Biologics LLC, a pharmaceutical technology company developing innovative platforms to improve biologic formulations and MilliporeSigma today announced a global license agreement and collaboration to commercialize proprietary ReForm excipients used in biotherapeutic formulations. The Life Science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. Under the agreement,
ReForm Biologics Announces Issuance of U.S. Patent on Additional Excipients for Therapeutic Protein Formulations
ReForm Biologics, a pharmaceutical technology company developing innovative platforms to improve biologic formulations, expanded its patent portfolio with the issuance of U.S. Patent No. 10,478,498 (the ‘498 patent)
Presentations on bio-layer interferometry for improved formulation screening and use of new excipients to prevent particle formation
ReForm Biologics Announces the Appointment of Alan Herman, Ph.D. and Fred Larimore, Ph.D. to Scientific Advisory Board
ReForm Biologics announced the appointment of Alan Herman, Ph.D. and Fred Larimore, Ph.D. to the company’s Scientific Advisory Board (SAB).
ReForm Biologics Announces An Evaluation Agreement for Enhancing Formulation of Two Clinical-stage Pipeline Programs
ReForm Biologics announced a new customer. ReForm will perform feasibility studies for Bayer AG utilizing its innovative biotherapeutic technologies.
ReForm Biologics Announces Issuance of U.S. Patent on Stabilizing Excipients for Therapeutic Protein Formulations
New class of excipients offers a promising alternative to polysorbates for stabilizing proteins
ReForm Biologics Announces New Patent on Surfactant Replacement Excipients to Stabilize Antibody-Based Therapeutics
New surfactant replacement offers a promising alternative to polysorbates for stabilizing proteins.
ReForm Biologics and KBI Biopharma Announce Strategic Partnership to Improve Biopharmaceutical Formulations and Development
Collaboration will provide clients competitive advantages, improve speed to market
ReForm Biologics Secures New Patent Expanding Coverage of Key Excipient Formulation for Antibody-Based Therapeutics
ReForm Biologics, a pharmaceutical technology company developing innovative platforms to improve biologic formulations, expanded its patent portfolio with the issuance of U.S. Patent No. 9,867,881 (the ‘881 patent).
ReForm Biologics Announces Issuance Of U.S. Patent For New Excipient To Improve Antibody-Based Therapeutics